A 40-year-old man presented to the emergency department with a 5-day history of fevers, sore throat, fatigue, subjective ...

Whether extended lymphadenectomy is associated with improved disease-free and overall survival, as compared with standard lymphadenectomy, among patients with localized muscle-invasive bladder ...

CAR T-cell manufacturing involves T-cell apheresis, CAR transduction, and expansion of transduced autologous or allogeneic T cells. To date, approved CAR T-cell products rely on lentiviral ...

CME activities, cases, challenges, videos, and more teaching and learning tools from the New England Journal of Medicine.

Hereditary hemorrhagic telangiectasia (HHT) is characterized by extensive telangiectasias and arteriovenous malformations. The primary clinical manifestation is epistaxis that results in iron ...

From the Department of Health Care Policy, Harvard Medical School, and the Division of General Internal Medicine and Primary Care, Brigham and Women’s Hospital — both in Boston (J.M.M.); and ...

U.S. states, which are better positioned than the federal government to precisely and comprehensively address the drivers of low-value health care spending, should lead the way in establishing ...

Welcome and thank you for considering the New England Journal of Medicine (NEJM) as a venue for your work. As the oldest continuously-published medical journal, our mission since 1812 has been to ...

Respiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the ...

Dr. John H. Stone: A 45-year-old woman was referred to the rheumatology clinic of this hospital because of retroperitoneal fibrosis and the possibility of IgG4-related disease. Seven years before ...

In order to ensure timely testing of drugs that have been granted accelerated approval, the FDA can impose civil monetary penalties on dilatory manufacturers — but has never done so. This ...

Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard ...